# Clinical Trials Data ALK - Document 21

# A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

## Clinical Trial: https://clinicaltrials.gov/study/NCT01712217

"eligibilityCriteria": "Inclusion Criteria:\n\n1. Men or women 18 years of age or older\n2. Must have Non-small Cell Lung Cancer with ALK+ mutation or other mutations or rearrangements potentially sensitive to crizotinib\n3. Measurable disease\n4. Must have been receiving or have received crizotinib\n5. Have adequate cardiac, bone marrow, liver and kidney function\n6. Must be willing and able to provide written informed consent and comply with the protocol and study procedures\n\nExclusion Criteria:\n\n1. Prior anti-cancer treatment with any HSP90 inhibitor\n2. Have received chemotherapy, radiation therapy or other anticancer treatment other than crizotinib within 3 weeks prior to the first dose of study drug\n3. Prior malignancy other than adequately treated basal or squamous cell carcinoma of the skin, superficial bladder cancer, low-grade cervical cancer, non-metastatic prostate cancer, or have been disease-free for at least 3 years\n4. Abnormal heart function\n5. Presence of a life-threatening illness, medical condition, organ system dysfunction, or other factors\n6. Hypersensitivity of AT13387 or other components of the drug product\n7. Treatment with an investigational drug within 3 weeks prior to the first dose of study drug\n8. Severe systemic diseases or active uncontrolled infections\n9. Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis C virus or hepatitis B virus",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
A patient with an ALK gene mutation \*could\* be eligible for this trial, but more information is needed.  
  
\*\*Reasons they might be eligible:\*\*  
  
\* \*\*Inclusion Criteria #2\*\* explicitly states that patients with NSCLC and an ALK+ mutation are eligible.  
  
\*\*Reasons they might NOT be eligible:\*\*  
  
The patient's eligibility depends on meeting \*all\* inclusion criteria and \*none\* of the exclusion criteria. We don't have enough information about the patient to determine this. For example:  
  
\* \*\*Inclusion Criteria #4:\*\* The patient must have received crizotinib in the past or be currently receiving it. This is a crucial piece of information missing from the question.  
\* \*\*Inclusion Criteria #5:\*\* We don't know about the patient's organ function.  
\* \*\*Inclusion Criteria #6:\*\* We don't know the patient's willingness to consent and comply.  
\* \*\*Exclusion Criteria:\*\* Any one of the exclusion criteria could disqualify the patient. We don't know about their prior treatments, other medical conditions, or HIV/Hepatitis status.  
  
In short, having the ALK mutation fulfills \*one\* requirement, but many other factors determine final eligibility.